NCT05700201 Investigating Cardiac Health of Adults With Trauma
| NCT ID | NCT05700201 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Southeastern University |
| Condition | Posttraumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 216 participants |
| Start Date | 2023-04-21 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 216 participants in total. It began in 2023-04-21 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project examines the impact of a healthy lifestyle intervention, specifically designed for adults with posttraumatic stress and identified cardiovascular risks.
Eligibility Criteria
Inclusion Criteria: * PTSD symptoms * overweight OR less than 30 min. of moderate physical activity 5 times per week Exclusion Criteria: * cannot exercise at a low-moderate level (walking)
Contact & Investigator
Jeffrey Kibler, PhD
PRINCIPAL INVESTIGATOR
Nova Southeastern University
Frequently Asked Questions
Who can join the NCT05700201 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Posttraumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05700201 currently recruiting?
Yes, NCT05700201 is actively recruiting participants. Contact the research team at whs.nsu@gmail.com for enrollment information.
Where is the NCT05700201 trial being conducted?
This trial is being conducted at Fort Lauderdale, United States.
Who is sponsoring the NCT05700201 clinical trial?
NCT05700201 is sponsored by Nova Southeastern University. The principal investigator is Jeffrey Kibler, PhD at Nova Southeastern University. The trial plans to enroll 216 participants.